This ten-year market analysis of visual technologies in healthcare examines nine sectors where imaging, computer vision and artificial intelligence will transform medicine and patient care.
Visual technologies traverse a patient’s journey from diagnosis, to treatment, to continuing care and prevention. Visual assessment is critical - whether that is a doctor peering down your throat as you say “ahhh” or an MRI of your brain. Visual technologies capture, analyze, process, filter and manage any visual data from images, videos, thermal, x-ray’s, ultrasound, MRI, CT scan, 2D, 3D, 4D, 6D and more.
Over the next ten years, healthcare workflows will become mostly digitized, more personal data will be captured and computer vision, along with artificial intelligence, will automate the analysis of that data for precision care. Much of the digitized data will be visual.
Visual technologies have deep implications for the future of personalized healthcare and will hopefully improve the health of people worldwide. It represents unique investment opportunities.
This 20-page report is the second of a multi-phased market analysis of the visual technology ecosystem by LDV Capital. Key findings include:
Healthcare in 2028 will be guided by doctors, owned by patients, and powered by visual tech.
Diagnosis of diseases can occur before symptoms are presented.
Computer vision and artificial intelligence will empower radiologists.
Miniaturization of imaging hardware will allow imaging to move into the exam room, operating room and even your living room.
Next-generation sequencing (NGS), next-generation phenotyping (NGP) and quantitative imaging will determine more effective, precision treatment plans.
3D imaging will improve surgery preparations and enable custom printing of bones and organs.
Scopes will guide surgeons through the majority of procedures and vision-guided robots will assist or perform surgeries.
The number of virtual doctors visits will surpass physical office visits.
Patients will collect exponential amounts of health data themselves for their own treatment, care and prevention.
Visual sensors in hospitals and healthcare facilities will make them more patient-centric, efficient and less expensive.
Patients will hopefully own their own healthcare data and access and share it from the cloud.
We look forward to hearing your insights, learning about your startups and reading your research papers on how businesses are addressing these challenges and opportunities.
Information in this report can be referenced and quoted with a hyperlink to this page and credit ©LDV Capital
Authors:
Evan Nisselson, General Partner
Abigail Hunter-Syed, Former Partner
Max Henkart, Summer Analyst
Ahmed Abdelsalam, Summer Analyst
Danilo Vicioso, Summer Analyst
Special thanks go out to the following individuals for sharing their insights and expertise with LDV Capital for the research behind this report:
Dr. Daniel Sodickson, Vice-Chair for Research at Dept of Radiology; Director at Bernard & Irene Schwartz Center for Biomedical Imaging; Principal Investigator at Center for Advanced Imaging Innovation & Research in New York University Langone Medical Center
Dekel Gelbman, Founder & CEO of FDNA
Dr. Emmanual Dumont, CEO of Shade, Research Associate in Epigenetics at Hackensack Medical School
Gaile Gordon, Expert in Residence at LDV Capital
Dr. David Rabuka, Global Head of R&D, Chemical Biology at Catalent Biologics; President of Redwood Bioscience, acquired by Catalent
Jack Kreindler, MD, Founder & Director, The Centre for Health and Human Performance
Jeff Nadler, CIO at Teladoc Health
Jeremiah Robison, Founder & CEO of Cionic
Dr. Laurent Hermoyne, CEO at Imagilys
Dr. Matthew Rosen, Director, Low Field MRI & Hyperpolarized Media Lab. Co-Director, Center for Machine Learning MGH/Martinos Center for Biomedical Imaging Harvard Medical School
Dr. Nina Tandon, CEO of Epibone
Philip Regenie, Founder & CEO of Zanthion
Richard Ha, MD, MS, Director of Research & Education. Breast Imaging Section. Associate Professor of Radiology at Columbia University Medical Center
Stefan Roever, CEO & Co-Founder of AIKON. Board Member at Peptilogics. Board Member at Espero Biopharma. Co-Founder of Genia Technologies acquired by Roche
Dr. Yamuna Krishnan, Co-Founder & Chief Science Officer at Esya Labs. Director of the Krishnan Lab and Professor of Chemistry at the University of Chicago
You might also be interested in reviewing other LDV Insights reports:
